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Prostaglandin E
2
(PGE
2
) is an endogenous lipidmediator, produced from themetabolism of arachidonic acids, upon the sequential
actions of phospholipase A2, cyclooxygenases, and prostaglandin E synthases. The various biological functions governed by PGE
2
are mediated through its four distinct prostaglandin E receptors (EPs), designated as EP1, EP2, EP3, and EP4, among which the
EP4 receptor is the one most widely distributed in the heart. The availability of global or cardiac-specific EP4 knockout mice and
the development of selective EP4 agonists/antagonists have provided substantial evidence to support the role of EP4 receptor in
the heart. However, like any good drama, activation of PGE
2
-EP4 signaling exerts both protective and detrimental effects in the
ischemic heart disease. Thus, the primary object of this review is to provide a comprehensive overview of the current progress of
the PGE
2
-EP4 signaling in ischemic heart diseases, including cardiac hypertrophy and myocardial ischemia/reperfusion injury. A
better understanding of PGE
2
-EP4 signaling should promote the development of more effective therapeutic approaches to treat the
ischemic heart diseases without triggering unwanted side effects.
1. Introduction
Ischemia of the heart resulting from the shortage of oxygen
supply can lead to the occurrence of myocardial ischemia/
reperfusion injury (MI/R), presenting as a leading cause of
mortality and morbidity especially in those with preexisting
myocardial diseases such as cardiac hypertrophy both in
developed and in developing countries [1]. In the general
population, the incidence of ischemic heart diseases increases
when a person becomes overweight or obese [2, 3], which
could be attributed to the alterations in the control of
coronary blood flow [4] or the dysregulation of adipocyte-
derived hormones (such as adiponectin, leptin) in the obesity
[5, 6]. The population of obesity has skyrocketed worldwide
over the last three decades [7]. In addition, overweight and
obesity were estimated to have caused 3.4 million deaths in
2010, most of which were from cardiovascular causes [8].
Therefore, examining ways to protect the ischemic heart and
its associated diseases (like obesity, metabolic syndrome) will
be of great clinical value in this industrialized world.
Prostaglandin E
2
(PGE
2
) is an endogenous lipidmediator,
which belongs to the family of eicosanoids [9]. Upon the
action of phospholipase A2, arachidonic acid, the precursor
of prostaglandins, is generated from phospholipids in the cell
membrane [10]. Arachidonic acid is then metabolized into
prostaglandin H2 by cyclooxygenase (COX) enzymes. Pros-
taglandin H2 is the first intermediate in the biosynthesis of
prostaglandins, which requires the action of specific prostagl-
andin synthases. The specific synthases involved in the for-
mation of PGE
2
are microsomal prostaglandin E synthases-
(mPGES-) 1 and mPGES-2 and cytosolic PGE
2
synthases
(cPGES) [9, 11]. PGE
2
exerts its diverse effects by activating
four subtypes of prostaglandin E receptors (EPs), designated
as EP1, EP2, EP3, and EP4 [12]. Of those, the EP4 receptor is
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themost widely distributed subtype which exists in almost all
tissues, such as the heart, adipose tissue, skeletal muscle, and
lung [13–15], and is involved in various pathophysiological
processes [16–18]. In particular, mice lacking EP4 exhibited
slower weight gain and reduced adiposity upon high fat diet
challenge when compared with wild typemice [16]. However,
the lean phenotype of EP4 knockout mice is not a beneficial
factor. In fact, EP4 knockoutmice had a shorter life span than
did the wild type mice [16]. In addition, deficiency of EP4 in
mice manifests disrupted lipid metabolism due to impaired
triglyceride clearance, suggesting a new dimension role of
EP4 signaling in controlling lipid homeostasis [16]. Activa-
tion of PGE
2
-EP4 signaling also can exert multiple biochemi-
cal effects on the heart, suggesting the potential wide-ranging
use of EP4 in both cardiovascular and metabolic disorders.
However, due to the limited reports of EP4 in ischemic heart
under complicated disease states, in this review, we thus
summarize the current progress regarding the role of the
PGE
2
-EP4 signaling in ischemic heart diseases, including
cardiac hypertrophy and MI/R, which has been obtained
from studies using genetic knockout mouse and pharmaco-
logical interventions.
2. Prostaglandin E Receptor Subtype 4:
Structure and Signaling
As one of the seven-transmembrane G-protein-coupled
receptors, EP4 (originally misidentified as EP2 subtype [19])
shares the structure properties of G-protein-coupled recep-
tors. It has an extracellular N-terminus, a seven-transmem-
brane domain connected by three extracellular loops and three
intracellular loops, and an intracellular C-terminus [20]. The
N-glycosylation sites in the second extracellular loop of EP4
are important for the ligand binding [21]. EP4 has the longest
intracellular C-terminus and third intracellular loop out of
the four EP receptors. The human EP4 receptor is comprised
of 488 amino acid residues, while the murine EP4 receptor
has two isoform variants that consist of 488 and 513 amino
acid residues, respectively [22, 23]. The sequence homology
of EP4 between these two species reaches up to 88% [21].
Thedownstream effectors ofG-protein-coupled receptors
are G-proteins, which consist of 𝛼, 𝛽, and 𝛾 subunits. Upon
ligand binding, the conformational change in G-protein-
coupled receptors triggers the dissociation of G𝛼 from the
G𝛽𝛾 subunits [22]. EP4 is coupled to stimulated G𝛼 (Gs𝛼),
which leads to the production of cyclic adenosinemonophos-
phate (cAMP) in response to PGE
2
[23]. The increased intra-
cellular cAMP level subsequently activates its major target
protein kinase A (PKA). PKA then phosphorylates down-
stream protein, cAMP response element binding protein
(CREBP), which is a nuclear transcriptional factor [24]. The
activated CREBP then binds to specific sites and regulates the
expression of certain genes, such as B-cell lymphoma 2 and
tumor necrosis factor 𝛼 (TNF𝛼), which are involved in devel-
opment of ischemic heart disease [25]. In addition to PKA,
another downstream molecule of Gs𝛼/cAMP is exchange
protein directly activated by cAMP (Epac). Epac consists
of Epac1 and Epac2. Both Epac isoforms can convert their
downstream protein Ras-related protein 1 from inactivated
guanosine diphosphate form to activated guanosine triphos-
phate form, which leads to the initiation of downstream sig-
naling cascades [26]. EP4 is also coupled to the inhibitory G𝛼
(Gi𝛼) [27]. In response to PGE
2
, Gi𝛼 inhibits adenylyl cyclase
activity leading to the reduced production of cAMP [28].
Furthermore, through activation of Gi𝛼, EP4 mediates phos-
phatidylinositol 3-kinase- (PI3K-) dependent pathway [29].
Activation of PI3K inhibits PKA activity but activates protein
kinase B, which also can phosphorylate CREBP [30]. On
the other hand, EP4 induces the expression of early growth
response factor 1 through the PI3K/extracellular signal-
regulated kinase (ERK) signaling pathway, which leads to the
expression of PGE
2
synthase, suggesting a positive feedback
loop between EP4 and PGE
2
production [23, 31]. Furthermore,
yeast two-hybrid screening of human bone marrow comple-
mentary DNA with EP4 protein reveals that a protein named
prostaglandin E receptor 4-associated protein (EPRAP) binds
to the intracellular C-terminus of EP4 [32]. The interaction
of EPRAP and EP4 inhibits stimulus-induced NF𝜅B p105
phosphorylation and thus suppresses activation of NF𝜅B [33]
(Figure 1).
Besides EP4 receptor, there are another three GPCRs,
EP1, EP2, and EP3, which depend on G-protein to transduce
downstream signals and mediate PGE
2
actions [12]. EP1
receptor couples to Gq𝛼 protein and thus induces phos-
pholipase C/inositol-1,4,5-trisphosphate signaling and leads
to intracellular calcium mobilization [34]. The same as EP4
receptor, EP2 couples to Gs𝛼 protein and activates adenylate
cyclase to produce cAMP, while EP3 is associated with Gi𝛼
and inhibits cAMP production [35]. These EP subtypes have
their unique expression patterns and associate to distinct
downstream G-proteins and thereby lead to PGE
2
being the
most versatile prostanoid.
3. Myocardial Ischemia/Reperfusion Injury
Myocardial ischemia caused by partial or complete occlusion
of coronary arteries and the subsequent recovery of blood
flow induced additional cardiac damage (ischemia/reperfu-
sion injury) are leading causes for death around the world
[36]. The underlying pathophysiology of myocardial I/R
injury likely involves many factors, such as reactive oxygen
species formation [37], altered cardiac energy metabolism
[38], activation of cell apoptosis [39], and inflammatory
responses [40].
During cardiac ischemia, the PGE
2
level is significantly
increased [41], and this increase may be a consequence of
hypoxia inducible factor- (HIF-) 1𝛼/COX-2/PGE
2
pathway
activation. Under ischemia conditions, theHIF-1𝛼 level starts
to accumulate in the nucleus, be heterodimerized with 𝛽
subunit, and initiate the transcription of genes which are
involved in cell survival, angiogenesis, apoptosis, vascular
remodeling, and glucose metabolism [42]. COX-2 has been
proved to be a downstream protein of HIF-1𝛼 in various cell
types, such as carcinoma cell lines HT29 [43] and human
bronchial epithelial BEAS-2B cells [44]. COX-2 has been
reported to be induced in the heart during I/R [45] and
its expression was positively associated with the expression
of HIF-1𝛼 at the site of recent acute myocardial infarction
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Figure 1: Differential signaling pathway of EP4. In response to PGE
2
, activation of EP4 stimulates stimulatoryG𝛼 protein (Gs𝛼)/cyclic adeno-
sine monophosphate (cAMP)/protein kinase A (PKA)/cAMP response element binding protein (CREB) pathway or Gs𝛼/cAMP/exchange
protein directly activated by cAMP (Epac) pathway. EP4 is also coupled to inhibitory G𝛼 protein (Gi𝛼), which inhibits the cAMP/PKA/CREB
pathway. Furthermore, EP4 activates phosphatidylinositol 3-kinase (PI3K) through activation of Gi𝛼. Activation of PI3K not only stimulates
the protein kinase B (PKB)/CREB pathway but also induces the expression of early growth response factor 1 (EGR-1) through extracellular
signal-regulated kinase signaling. Prostaglandin E receptor 4-associated protein (EPRAP) can inhibit phosphorylation of p105 and further
suppress the activation of nuclear factor kappa B (NF𝜅B). AC = adenylyl cyclase; ATP = adenosine triphosphate; GDP = guanosine
diphosphate; GTP = guanosine triphosphate.
[46], despite the fact that direct evidence regarding whether
or not COX-2 was transcriptionally controlled by HIF-1𝛼 in
cardiomyocytes is lacking. Thus, as the major metabolite of
COX-2, cardiac PGE
2
may be produced through HIF-1𝛼/
COX-2 axis during cardiac ischemia.
The increased PGE
2
level may play a beneficial role
during cardiac I/R through EP4 receptor [15, 47]. Indeed,
endogenous PGE
2
protects the heart from I/R injury in vitro
and in vivo [15]. In isolated perfused working hearts, there
was a greater degree of functional damage to themyocardium
(e.g., decreased developed tension, increased diastolic tension
and creatine kinase (marker of myocardial injury) release) in
EP4 knockout hearts after global ischemia when compared
with wild type hearts [15]. In accordance with this result,
mice lacking EP4 developed a greater degree of myocardial
infarction size following I/R injury when compared with wild
type mice in vivo [15]. Likewise, pharmacological interven-
tionwith an EP4 agonist significantly reduced infarct size and
improved cardiac function, including left ventricular con-
traction and dilatation when compared with vehicle treated
animals [47]. In line with this, the ischemic preconditioning-
induced cardioprotection is completely lost in HIF-1𝛼+/−
mice [48]. Deficiency of hypoxia inducible transcription
factor-prolyl hydroxylase domain-1 (PHD-1) in the mice sig-
nificantly attenuated MI/R injury through reduced apoptosis
by induction of HIF-1𝛼 [49], and COX-2 serves a protective
role against myocardial I/R injury [50, 51].These data provide
additional evidence that PGE
2
-EP4 signaling sourced from
HIF-1𝛼/COX-2 axis is cardioprotective in the ischemic heart.
The subsequent downstream signaling of EP4 during the
myocardial I/R injury has not been well documented yet.
However, there are multiple potential downstream pathways.
(1) cAMP-PKA pathway: Through the activation of EP4
receptor on the cell membrane, adenylyl cyclase catalyzes the
conversion of adenosine triphosphate to cAMP. There are at
least 9 isoforms of adenylyl cyclase; among them, adenylyl
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Figure 2: Schematic representation of the proposed role of EP4-mediated signaling under myocardial ischemia. During cardiac ischemia,
increased PGE
2
level may be a consequence of increased hypoxia inducible factor- (HIF-) 1𝛼/cyclooxygenase-2 (COX-2) activation. PGE
2
may play a beneficial role in cardiac ischemia/reperfusion injury through EP4/cyclic adenosine monophosphate (cAMP)/protein kinase A
(PKA) or EP4/signal transducer and activator of transcription 3 (Stat3) signaling pathway. In addition, synthesized PGE
2
in cardiomyocytes
also diffuses into adjacent infiltrated macrophages or other inflammatory cells, protects the heart from ischemia/reperfusion injury through
binding with EP4 receptor, and exerts anti-inflammatory effects.
cyclase V and adenylyl cyclase VI are mainly expressed in
the mammalian myocardium [52]. In the mice with cardiac
adenylyl cyclase VI overexpression, adverse left ventricular
remodeling was attenuated with preserved left ventricular
contractile function and reduced mortality after myocardial
ischemia [53]. In addition, through activating the down-
stream protein cAMP, PKA presents a cardioprotective role
after ischemia possibly through its negative-inotropic effect
during sustained ischemia [54]. In this study, the negative-
inotropic effects of postischemic effluent can be significantly
suppressed by preincubation with EP2 antagonist (AH6809)
or EP4 antagonist (AH23848), indicating a protective role of
bothEP2 andEP4 receptor during I/R injury.However, unlike
EP4 receptor, there is still no direct evidence showing that
EP2 receptor can mediate the cardioprotective role of PGE
2
in the postischemic heart during reperfusion in vivo and
this warrants further investigation.These data suggested that
cAMP-PKA may be responsible for the PGE
2
-EP4-mediated
cardioprotection during myocardial ischemia. (2) Stat3 sig-
naling: In addition to its role in the cardiac hypertrophy,
Stat3 signaling activation also plays a causal role in ischemic
postconditioning mediated cardioprotection [5]. Multiple
lines of evidence suggested that activation of Stat3 signaling
exerts cardioprotective effects during I/R injury through
scavenging of reactive oxygen species [55] or improvingmito-
chondrial function [56]. In cardiomyocytes, PGE
2
activated
Stat3 signaling through EP4 receptor in a concentration-
and time-dependent manner [57]. Moreover, MI/R-induced
tissue injury involves activation of cell apoptosis [39]. PGE
2
is
reported to prevent myocardial apoptosis through activation
of Stat3 and ERK1/2 in doxorubicin-induced apoptosis model
in neonatal rat ventricular cardiomyocytes [58], suggesting
that activation of Stat3 signaling may contribute to PGE
2
-
EP4-mediated cardioprotective role during I/R injury. In
addition, despite the fact that there is no direct evidence
showing that activation of EP4 receptor exerts antiapoptotic
role in cardiomyocytes during I/R injury, it has been proved
that PGE
2
protects normal and transformed intestinal epithe-
lial cells from diverse stimuli-induced apoptosis via EP4
receptor [59]. Consistently, another study showed that EP4
agonist (L-902688) significantly inhibits the cell death during
in vivo focal cerebral ischemia [60]. Taken together, these data
suggested that PGE
2
-EP4 signaling may mediate cardiopro-
tection through attenuating cell apoptosis during myocardial
ischemia.
During ischemia, inflammatory cells like macrophages
may migrate into the ischemic myocardium and pro-
duce proinflammatory cytokines and chemokines, including
TNF𝛼, interleukin 6 (IL6), IL-1𝛽, and monocyte chemotactic
protein 1 (MCP-1), which further exacerbate myocardial I/R
injury [40]. Thus, it is possible that the anti-inflammatory
effect of EP4 onmacrophagesmay contribute to the beneficial
role of EP4 in cardiac ischemia. Indeed, EP4 agonist signifi-
cantly attenuated the production of TNF𝛼, IL-6, IL-1𝛽, and
MCP-1 as well as macrophage infiltration in the heart after
ischemia [47]. Of note, the EP4-Stat3 signaling may establish
a positive feedback loop through controlling the expression
of COX-2 in cardiomyocytes, while the newly secreted PGE
2
may not only trigger greater Stat3 activation but also exert
anti-inflammatory effect on infiltrated inflammatory cells in
a paracrine way (Figure 2). Thus, EP4 receptor may confer
protection against I/R injury at multiple levels. EP4 agonist
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may provide a novel approach to limit the damage from
myocardial I/R injury.
4. Cardiac Hypertrophy
Pathological cardiac hypertrophy is a slow adaptive response
to various types of extracellular stressors, including increased
hemodynamic load [61], neurohormones [62], growth fac-
tors [63], and cytokines [64]. At the early stage, cardiac
hypertrophy is compensatory to maintain the circulatory
system homeostasis. However, the severe and sustained
workload on the heart may trigger the cardiac remodeling
process and increase the risk of cardiac dysfunction and,
ultimately, the development of heart failure [65] and the
underlying mechanism is incompletely understood. A better
understanding of the signal transmission from cell surface
to the nuclear transcription activities in response to various
hypertrophic stimuli may yield novel therapeutic approaches
to treat cardiac hypertrophy.
In ventricular myocytes, PGE
2
significantly increased
total protein synthesis (measured by [3H]-phenylalanine
uptake), cell surface area, and hypertrophic maker genes,
including atrial natriuretic peptide (ANP) and brain natri-
uretic peptide (BNP), in a dose dependent manner [66–68].
These hypertrophic effects of PGE
2
were conserved in vivo.
Using a mouse model of myocardial infarction, injection
with NS-398 or rofecoxib (COX-2 selective inhibitors) in
mice significantly downregulated cardiac PGE
2
production
and reduced cardiac hypertrophy as determined by myocyte
cross-sectional area when compared with vehicle treated
mice [69]. Similarly, mice with global knockout of mPGES-
1, which is in charge of the inducible PGE
2
synthase, also
exhibited decreased cardiac PGE
2
levels, myocyte cross-
sectional area, and cardiomyocyte surface area after myocar-
dial infarction when compared to wild type mice, suggesting
that PGE
2
positively regulates cardiac hypertrophy in vitro
and in vivo [70].
Activation of EP4 receptor signaling contributes to
the PGE
2
-mediated cardiac hypertrophy, since EP4 specific
antagonist (L-161982 or ONO-AE3-208) significantly blocked
the hypertrophic actions of PGE
2
, including the protein
synthesis, mRNA expression of ANP and BNP in neonatal
cardiac cells [66, 68]. In accordance with these observa-
tions, myocyte cross-sectional area was significantly smaller
in cardiac-specific EP4 knockout mice after myocardial
infarction when compared with wild type mice, suggesting
that the lack of EP4 receptor signaling in cardiomyocytes
alleviated cardiac hypertrophy after myocardial infarction
[71]. By contrast, global EP4 knockout mice did not affect
the myocyte cross-sectional area and heart/body weight ratio
under basal conditions [15] or pressure overload-induced
cardiac hypertrophy through transverse aortic constriction
(TAC) treatment [72] as compared with wild type mice.
There are several possible explanations regarding the discrep-
ancy among these studies. (1) The development of cardiac
hypertrophy is a very slow process, and thus if there are no
continuous hypertrophic stimuli, it may take a long time to
develop cardiac hypertrophy. Therefore, it may be difficult
to detect significant difference in the development of cardiac
hypertrophy between EP4 wild type and knockout mice
under basal conditions. (2) The wide distribution of EP4
receptor in different kinds of cells indicates its diverse biologi-
cal functions in vivo, such as anti-inflammatory response [73]
and energy metabolism [16]. The affected anti-inflammatory
pathway or lipid metabolism in global EP4 knockout mice
may influence the development of cardiac hypertrophy indi-
rectly. Indeed, inflammatory process and energy metabolism
are closely associated with the pathogenesis of cardiac
hypertrophy [74, 75]. Thus, under basal condition or TAC-
induced cardiac hypertrophy, global knockout of EP4 in
mice may affect the pathogenesis of cardiac hypertrophy
through other compensatory pathways. (3) Different cardiac
hypertrophic stimuli activate diverse signaling cascades and
may have distinct cardiomyocyte gene expression pattern
[65]. It is possible that PGE
2
-EP4 signaling is only involved in
myocardial infarction—but not pressure overload-mediated
cardiac hypertrophy. (4) In the study of Hara et al. [72], the
heart/body weight ratios were only compared between EP4
wild type and knockout mice after 4 weeks of TAC treatment,
a time point atwhich generally the pressure overload-induced
cardiac hypertrophy has reached the maximal level. Thus,
comparison should be performed at both the early and late
phase of the disease to get a solid conclusion. Through
these explanations, it is tempting to speculate that EP4 in
cardiomyocytesmay be the endogenous ligand tomediate the
hypertrophic effects of PGE
2
both in vitro and in vivo, but its
definite role in this pathology needs to be confirmed in future
studies.
The additional challenge is to identify the subsequent
downstream molecules in EP4-mediated cardiac hypertro-
phy. Mammalian target of rapamycin (mTOR) has emerged
as an important regulator of cardiac hypertrophy [76]. There
is study that reported that PGE
2
activates themTOR complex
1 pathway through an EP4/cAMP/PKAmediatedmechanism
in the human pancreatic carcinoma cell line PANC-1 [77].
Besides PKA, cAMP also exerts its biological functions
through Epac. Despite the fact that cAMP-producing 𝛽-
adrenergic stimulation induces cardiac hypertrophy [78],
cAMP/PKA or cAMP/Epac signaling is not likely to mediate
the hypertrophic effects of PGE
2
in cardiomyocytes, since
all the treatment like cAMP activator (forskolin), cAMP
inhibitor (SQ-22536), PKA inhibitor (H89), and Epac acti-
vator (8-CPT-2Me-cAMP) at different concentrations had
no effect on PGE
2
-induced protein synthesis in ventricular
myocytes [57, 68, 79]. Thus, mTOR may not be able to medi-
ate the hypertrophic effects of PGE
2
/EP4 in cardiomyocytes.
It is well known that mitogen-activated protein kinases
(MAPKs) signaling cascade is a prominent player involved
in the hypertrophic reaction with its four best charac-
terized subfamilies, extracellular signal-regulated kinases
(ERK1/2 or P42/P44 MAPK), c-Jun N-terminal kinase
(JNK), p38 MAPK, and ERK5 [80]. The ERK1/2 inhibitor,
U0126, significantly reduced the hypertrophic effect of PGE
2
in ventricular myocytes, whereas the p38 MAPK blocker
(SB203580) and JNK inhibitor (SP600125) have no such
effect [68]. In addition, activation of ERK1/2 by PGE
2
was
strongly suppressed by EP4 antagonist ONO-208 compound,
indicating that ERK1/2 signaling cascade was involved in
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Figure 3: Simplified scheme of the EP4 signaling in PGE
2
-mediated hypertrophic actions. In response to PGE
2
, activation of EP4
transactivates epidermal growth factor receptors (EGFR), which can result in the activation of extracellular signal-regulated kinases (ERK1/2).
ERK1/2 in turn activated signal transducer and activator of transcription 3 (Stat3) pathway. Once Stat3 signaling is activated in the nucleus, the
hypertrophic genes will be expressed to mediate the protein synthesis. In addition, cyclooxygenase-2 (COX-2) expression is also stimulated
by Stat3 signaling, which will further metabolize the formation of PGE
2
from arachidonic acid (AA) and trigger the greater activation of Stat3
signaling in a positive feedback loop. Cyclic adenosine monophosphate (cAMP)/protein kinase A (PKA) or cAMP/exchange protein directly
activated by cAMP (Epac) pathways are not involved in the PGE
2
-EP4-mediated hypertrophic actions in ventricular myocytes.
PGE
2
-EP4-mediated cardiac hypertrophy [57, 68]. However,
the involvement of ERK5 on PGE
2
-induced protein synthesis
remains undefined.
Activation of G-protein-coupled receptors has been
shown to transactivate epidermal growth factor receptors
(EGFR), which can result in the activation of ERK1/2 sig-
naling [81, 82]. Indeed, EP4 antagonist L-161982 significantly
inhibited the phosphorylation of EGFR by PGE
2
in ven-
tricular myocytes. Furthermore, EGFR inhibitor AG-1478
totally blocked activation of ERK1/2 by PGE
2
and PGE
2
-
EP4-mediated protein synthesis, suggesting that activation of
EGFR bridges PGE
2
/EP4 and ERK1/2 signaling and also is
responsible for PGE
2
-induced protein synthesis in cardiomy-
ocytes [79].
As reported in several studies, signal transducer and acti-
vator of transcription 3 (Stat3) pathway is another signaling
cascade that plays a major role in the development of cardiac
hypertrophy. Multiple in vitro and in vivo studies suggested
that activation of Stat3 promotes cardiomyocyte hypertrophy
in response to various stimuli through transcriptional control
of hypertrophic genes expression [83, 84]. PGE
2
induced
Stat3 activation in cardiomyocytes in a concentration- and
time-dependentmanner, while ERK1/2 inhibitor (U0126) and
EP4 antagonists (GW627368X or AH23848B) significantly
suppressed PGE
2
-induced Stat3 activation [57]. In Stat3-
silenced cardiomyocytes, the PGE
2
-mediated protein synthe-
sis was dramatically inhibited [57], suggesting that activation
of Stat3 works downstream of PGE
2
-EP4-ERK1/2-mediated
cardiac hypertrophy in vitro. Accordingly, myocardial infarc-
tion induced cardiac hypertrophy was accompanied with sig-
nificantly increased Stat-3 phosphorylation in wild type con-
trols, but the increase of Stat-3 phosphorylation was absent in
the heart from cardiomyocyte-specific EP4 knockout mouse,
suggesting that EP4-Stat3 signaling is conserved in vivo and
responsible for cardiac hypertrophy [71]. Furthermore, once
Stat3 signaling is activated in the nucleus, the gene expression
of COX-2 will be stimulated, which will metabolize the first
step in the formation of PGE
2
from arachidonic acid and
trigger the greater activation of Stat3 signaling in a positive
feedback loop [85]. Thus, these findings together demon-
strated the pathophysiological importance of PGE
2
signaling
through EP4-EGFR-ERK1/2-Stat3 cascade that was involved
in the development of cardiac hypertrophy (Figure 3).
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5. Conclusion
Cardiac hypertrophy is not only a risk factor for myocardial
ischemia, but also part of the response ofMI/R-induced tissue
injury, which further promotes the extent of ischemia. It is
very interesting that activation of PGE
2
-EP4 signaling may
impact on ischemic heart events through totally opposite
pathways. EP4maymediate the cardiac hypertrophy through
EGFR/ERK1/2/Stat3 signaling, whereas PGE
2
-EP4 signaling
may protect the heart from MI/R injury through cAMP/
PKA or Stat3 pathway. Despite the fact that there is still
no direct evidence showing the role of Stat3 signaling in
EP4-mediated cardioprotection, the in vivo model, cardiac-
specific EP4 knockout mice with myocardial infarction,
exhibited decreased hypertrophic changes but worsened car-
diac function, suggesting that activation of EP4 signalingmay
contribute to the compensatory survival of cardiomyocytes
for maintaining the normal cardiac function. In the future,
with regard to the potential detrimental effects of EP4, special
caution is neededwhen evaluating how EP4 can be preferably
activated in the heart without triggering unwanted side
effects. In addition, the role of PGE
2
-EP4 signaling pathway
in the heart should be further explored in detail, with the
aim of developing therapeutic approaches to treat the patients
with ischemic heart disease and its associated diseases.
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